Literature DB >> 10912746

Comparison of three blood pressure measurement methods for the evaluation of two antihypertensive drugs: feasibility, agreement, and reproducibility of blood pressure response.

S Ragot1, N Genès, L Vaur, D Herpin.   

Abstract

Our objective was to compare three different methods of blood pressure measurement through the results of a controlled study aimed at comparing the antihypertensive effects of trandolapril and losartan. Two hundred and twenty-nine hypertensive patients were randomized in a double-blind parallel group study. After a 3-week placebo period, they received either 2 mg trandolapril or 50 mg losartan once daily for 6 weeks. At the end of both placebo and active treatment periods, three methods of blood pressure measurement were used: a) office blood pressure (three consecutive measurements); b) home self blood pressure measurements (SBPM), consisting of three consecutive measurements performed at home in the morning and in the evening for 7 consecutive days; and c) ambulatory blood pressure measurements (ABPM), 24-h BP recordings with three measurements per hour. Of the 229 patients, 199 (87%) performed at least 12 valid SBPM measurements during both placebo and treatment periods, whereas only 160 (70%) performed good quality 24-h ABPM recordings during both periods (P < .0001). One hundred-forty patients performed the three methods of measurement well. At baseline and with treatment, agreement between office measurements and ABPM or SBPM was weak. Conversely, there was a good agreement between ABPM and SBPM. The mean difference (SBP/DBP) between ABPM and SBPM was 4.6 +/- 10.4/3.5 +/- 7.1 at baseline and 3.5 +/- 10.0/4.0 +/- 7.0 at the end of the treatment period. The correlation between SBPM and ABPM expressed by the r coefficient and the P values were the following: at baseline 0.79/0.70 (< 0.001/< .0001), with active treatment 0.74/0.69 (0.0001/.0001). Hourly and 24-h reproducibility of blood pressure response was quantified by the standard deviation of BP response. Compared with office blood pressure, both global and hourly SBPM responses exhibited a lower standard deviation. Hourly reproducibility of SBPM response (10.8 mm Hg/6.9 mm Hg) was lower than hourly reproducibility of ABPM response (15.6 mm Hg/11.9 mm Hg). In conclusion, SBPM was easier to perform than ABPM. There was a good agreement between these two methods whereas concordance between SBPM or ABPM and office measurements was weak. As hourly reproducibility of SBPM response is better than reproducibility of both hourly ABPM and office BP response, SBPM seems to be the most appropriate method for evaluating residual antihypertensive effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10912746     DOI: 10.1016/s0895-7061(99)00258-7

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  14 in total

Review 1.  Clinical significance of home blood pressure and its possible practical application.

Authors:  Yutaka Imai
Journal:  Clin Exp Nephrol       Date:  2013-07-03       Impact factor: 2.801

2.  Changes in home versus clinic blood pressure with antihypertensive treatments: a meta-analysis.

Authors:  Joji Ishikawa; Deirdre J Carroll; Sujith Kuruvilla; Joseph E Schwartz; Thomas G Pickering
Journal:  Hypertension       Date:  2008-09-22       Impact factor: 10.190

3.  The International Database of HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO): moving from baseline characteristics to research perspectives.

Authors:  Teemu J Niiranen; Lutgarde Thijs; Kei Asayama; Jouni K Johansson; Takayoshi Ohkubo; Masahiro Kikuya; José Boggia; Atsushi Hozawa; Edgardo Sandoya; George S Stergiou; Ichiro Tsuji; Antti M Jula; Yutaka Imai; Jan A Staessen
Journal:  Hypertens Res       Date:  2012-07-05       Impact factor: 3.872

4.  Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.

Authors:  Silke Ewald; Johannes vor dem Esche; Sakir Uen; Fabian Neikes; Hans Vetter; Thomas Mengden
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 5.  Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis.

Authors:  Harikrishna Makani; Sripal Bangalore; Azhar Supariwala; Jorge Romero; Edgar Argulian; Franz H Messerli
Journal:  Eur Heart J       Date:  2013-08-21       Impact factor: 29.983

Review 6.  Home monitoring of blood pressure.

Authors:  Barry P McGrath
Journal:  Aust Prescr       Date:  2015-02-02

7.  Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.

Authors:  Yan Gong; Caitrin W McDonough; Zhiying Wang; Wei Hou; Rhonda M Cooper-DeHoff; Taimour Y Langaee; Amber L Beitelshees; Arlene B Chapman; John G Gums; Kent R Bailey; Eric Boerwinkle; Stephen T Turner; Julie A Johnson
Journal:  Circ Cardiovasc Genet       Date:  2012-10-19

8.  Reproducibility of blood pressure response to hydrochlorothiazide.

Authors:  Javier D Finkielman; Gary L Schwartz; Arlene B Chapman; Eric Boerwinkle; Stephen T Turner
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

9.  Reproducibility of wrist home blood pressure measurement with position sensor and automatic data storage.

Authors:  Sakir Uen; Rolf Fimmers; Miriam Brieger; Georg Nickenig; Thomas Mengden
Journal:  BMC Cardiovasc Disord       Date:  2009-05-27       Impact factor: 2.298

10.  Outcome-driven thresholds for home blood pressure measurement: international database of home blood pressure in relation to cardiovascular outcome.

Authors:  Teemu J Niiranen; Kei Asayama; Lutgarde Thijs; Jouni K Johansson; Takayoshi Ohkubo; Masahiro Kikuya; José Boggia; Atsushi Hozawa; Edgardo Sandoya; George S Stergiou; Ichiro Tsuji; Antti M Jula; Yutaka Imai; Jan A Staessen
Journal:  Hypertension       Date:  2012-11-05       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.